AGIO AGIOS PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1439222 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY214.4%
TTM net income YoY7.1%
TTM EPS YoY10.0%
Revenue 3-yr CAGR80.3%
Net income 3-yr CAGR—
Margins
Gross margin93.8%
Operating margin-297.7%
Net margin-264.8%
FCF margin-238.5%
EBITDA margin—
Returns
ROE-32.9%
ROA-30.4%
ROIC (approx.)-32.4%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets8.0%
Debt / equity0.00x
Current ratio9.69x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $54.03M | $36.50M |
| Cost of revenue | $6.34M | $4.17M |
| Gross profit | $47.68M | $32.33M |
| R&D expense | $339.54M | $301.29M |
| SG&A expense | $180.28M | $156.78M |
| Operating income | -$472.13M | -$425.74M |
| Pretax income | -$413.80M | $717.97M |
| Income tax | -$1.02M | $44.24M |
| Net income | -$412.78M | $673.73M |
| EBITDA | -$466.93M | -$420.04M |
| EPS (basic) | -7.12 | 11.86 |
| EPS (diluted) | -7.12 | 11.64 |
| Weighted avg. shares (diluted) | 57.97M | 57.89M |
| Balance sheet | ||
| Cash & equivalents | $89.13M | $76.25M |
| Short-term investments | $765.29M | $817.46M |
| Inventory | $32.92M | $27.62M |
| Current assets | $942.05M | $965.60M |
| PP&E, net | $10.78M | $11.68M |
| Total assets | $1.30B | $1.66B |
| Current liabilities | $82.21M | $81.16M |
| Total liabilities | $104.11M | $122.24M |
| Shareholders' equity | $1.19B | $1.54B |
| Shares outstanding | 58.45M | 57.16M |
| Cash flow statement | ||
| Operating cash flow | -$372.98M | -$389.84M |
| Capital expenditure | $4.32M | $1.69M |
| Free cash flow | -$377.29M | -$391.53M |
| Investing cash flow | $377.18M | $363.44M |
| Financing cash flow | $8.68M | $14.44M |
| Depreciation & amortization | $5.20M | $5.70M |
| Stock-based compensation | $52.55M | $42.85M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.